TOKYO, Mar 31 (Pulse News Wire) – CellSeed Inc. (7776.T) reported a revenue decline for its fiscal year ending December 2025 due to policy changes affecting overseas sales.
The company forecasts a continued reduction in revenues for the fiscal year ending December 2026, projecting a lower net profit of approximately ¥71 million compared to a previous estimate of ¥32 million. In the second quarter of FY2025, CellSeed recorded a lower net profit of ¥660 million, down from a loss of ¥580 million in the same period last year. The company attributes the reduced performance to increased development costs associated with clinical trials for tissue-engineered cartilage sheets and geopolitical risks impacting research activities abroad.
For FY2026, CellSeed plans to focus on expanding its overseas customer base through aggressive marketing efforts and accelerating the global rollout of its high-capacity cell culture flask, UpCell. Additionally, the firm aims to secure new manufacturing contracts and enhance production efficiency while addressing ongoing litigation with MetaTech(AP)Inc., which is expected to have no immediate impact on current operations. To support future growth, CellSeed has issued two tranches of subscription rights, raising funds for research and development, facility operations, and working capital.
The company remains committed to advancing its pipeline projects and securing additional partnerships to drive long-term profitability.
🟡 Confidence: Standard AI-translated content.